Research Links

Aug 27, 2007 (PRNewswire-Diamyd Medical AB)- Diamyd Medical announced today that NP2, the company's first drug candidate in its nerve targeting drug delivery system (NTDDS) gene therapy platform, will be the subject of a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration on August 29, 2007...

By Felice J. Freyer, Aug 26, 2007 (projo.com)- Asked about the major award he just won, Brown University brain scientist John P. Donoghue reaches across his desk for his invitation to the upcoming ceremony in Germany.

He opens it carefully and points to the names of the eminent scientists who will be there with him. “I’m flattered,” Donoghue says. “I’m honored to be among them...

Aug 10, 2007 (Genetic Engeneering &Biotechnology News, Business Wire)- Harvard Stem Cell Institute, Genetics Policy Institute, and Burrill Life Sciences Media Group, a joint venture of Nielsen Business Media and Burrill & Company, will host a landmark event focusing on the future of stem cell research and its potential to advance treatments for millions suffering from devastating medical conditions...

By Katie DeRosa, Aug11, 2007 (St. Catharines Standard- Osprey Media)- Janet Driessen gestures with enthusiasm as she talks about her disease, stopping only to calm her hyperactive aid dog, Detour, as he bounds around the room.

Her face is warm, youthful, healthy looking. Every few minutes, she reaches under her knees and tugs at her legs, repositioning one at a time the way they sit below the rest of her body...

Aug. 7, 2007 (PRNewswire-USNewswire)- In a study published in the August issue of Nature Neuroscience, researchers at the Kennedy Krieger Institute in Baltimore, Maryland found that there are separate adaptable networks controlling each leg and there are also separate networks controlling leg movements, e.g., forward or backward walking. These findings are contrary to the currently accepted theory that leg movements and adaptations are directed by a single control circuit in the brain...

By Kristen Philipkoski, Aug 08, 2007 (Wired Science)- There's been lots of confusion and some mischaracterizations about when the first embryonic stem cell clinical trial might take place and what it might treat. Spinal cord injury has been a leading candidate. Hans Keirstead, a scientist at the University of California at Irvine has been at the center of the discussions. His work, which has helped rats with severed spinal cords "walk" again...